These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

72 related items for PubMed ID: 20457522

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Cell-based biological evaluation of a new bisamide FMS kinase inhibitor possessing pyrrolo[3,2-c]pyridine scaffold.
    El-Gamal MI, Abdel-Maksoud MS, El-Din MM, Yoo KH, Baek D, Oh CH.
    Arch Pharm (Weinheim); 2014 Sep; 347(9):635-41. PubMed ID: 24942978
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance.
    Taylor JR, Brownlow N, Domin J, Dibb NJ.
    Oncogene; 2006 Jan 05; 25(1):147-51. PubMed ID: 16170366
    [Abstract] [Full Text] [Related]

  • 5. Discovery of novel FMS kinase inhibitors as anti-inflammatory agents.
    Illig CR, Chen J, Wall MJ, Wilson KJ, Ballentine SK, Rudolph MJ, DesJarlais RL, Chen Y, Schubert C, Petrounia I, Crysler CS, Molloy CJ, Chaikin MA, Manthey CL, Player MR, Tomczuk BE, Meegalla SK.
    Bioorg Med Chem Lett; 2008 Mar 01; 18(5):1642-8. PubMed ID: 18242992
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. FMIP, a novel Fms-interacting protein, affects granulocyte/macrophage differentiation.
    Tamura T, Mancini A, Joos H, Koch A, Hakim C, Dumanski J, Weidner KM, Niemann H.
    Oncogene; 1999 Nov 11; 18(47):6488-95. PubMed ID: 10597251
    [Abstract] [Full Text] [Related]

  • 8. Pyridyl and thiazolyl bisamide CSF-1R inhibitors for the treatment of cancer.
    Scott DA, Aquila BM, Bebernitz GA, Cook DJ, Dakin LA, Deegan TL, Hattersley MM, Ioannidis S, Lyne PD, Omer CA, Ye M, Zheng X.
    Bioorg Med Chem Lett; 2008 Sep 01; 18(17):4794-7. PubMed ID: 18694641
    [Abstract] [Full Text] [Related]

  • 9. The M-CSF receptor substrate and interacting protein FMIP is governed in its subcellular localization by protein kinase C-mediated phosphorylation, and thereby potentiates M-CSF-mediated differentiation.
    Mancini A, Koch A, Whetton AD, Tamura T.
    Oncogene; 2004 Aug 26; 23(39):6581-9. PubMed ID: 15221008
    [Abstract] [Full Text] [Related]

  • 10. The fms gene and the CSF-1 receptor.
    Sherr CJ, Rettenmier CW.
    Cancer Surv; 1986 Aug 26; 5(2):221-32. PubMed ID: 3022923
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors.
    Illig CR, Manthey CL, Meegalla SK, Wall MJ, Chen J, Wilson KJ, DesJarlais RL, Ballentine SK, Schubert C, Crysler CS, Chen Y, Molloy CJ, Chaikin MA, Donatelli RR, Yurkow E, Zhou Z, Player MR, Tomczuk BE.
    Bioorg Med Chem Lett; 2013 Dec 01; 23(23):6363-9. PubMed ID: 24138939
    [Abstract] [Full Text] [Related]

  • 13. cAMP inhibits CSF-1-stimulated tyrosine phosphorylation but augments CSF-1R-mediated macrophage differentiation and ERK activation.
    Wilson NJ, Cross M, Nguyen T, Hamilton JA.
    FEBS J; 2005 Aug 01; 272(16):4141-52. PubMed ID: 16098196
    [Abstract] [Full Text] [Related]

  • 14. Pyrrolo[3,2-c]pyridine derivatives with potential inhibitory effect against FMS kinase: in vitro biological studies.
    El-Gamal MI, Oh CH.
    J Enzyme Inhib Med Chem; 2018 Dec 01; 33(1):1160-1166. PubMed ID: 30070930
    [Abstract] [Full Text] [Related]

  • 15. Transcriptional regulation of the c-fms proto-oncogene mediated by granulocyte/macrophage colony-stimulating factor (GM-CSF) in murine cell lines.
    Helftenbein G, Krusekopf K, Just U, Cross M, Ostertag W, Niemann H, Tamura T.
    Oncogene; 1996 Feb 15; 12(4):931-5. PubMed ID: 8632916
    [Abstract] [Full Text] [Related]

  • 16. Structure, biosynthesis and biological roles of monocyte-macrophage colony stimulating factor (CSF-1 or M-CSF).
    Praloran V.
    Nouv Rev Fr Hematol (1978); 1991 Feb 15; 33(4):323-33. PubMed ID: 1838150
    [Abstract] [Full Text] [Related]

  • 17. Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitors.
    Wilson KJ, Illig CR, Chen J, Wall MJ, Ballentine SK, DesJarlais RL, Chen Y, Schubert C, Donatelli R, Petrounia I, Crysler CS, Molloy CJ, Chaikin MA, Manthey CL, Player MR, Tomczuk BE, Meegalla SK.
    Bioorg Med Chem Lett; 2010 Jul 01; 20(13):3925-9. PubMed ID: 20570147
    [Abstract] [Full Text] [Related]

  • 18. STAP-2 regulates c-Fms/M-CSF receptor signaling in murine macrophage Raw 264.7 cells.
    Ikeda O, Sekine Y, Kakisaka M, Tsuji S, Muromoto R, Ohbayashi N, Oritani K, Yoshimura A, Matsuda T.
    Biochem Biophys Res Commun; 2007 Jul 06; 358(3):931-7. PubMed ID: 17512498
    [Abstract] [Full Text] [Related]

  • 19. Identification of tyrosine-phosphorylated colony-stimulating factor 1 (CSF-1) receptor and a 56-kilodalton protein phosphorylated in intact human cells in response to CSF-1.
    Huhn RD, Cicione ME, Frackelton AR.
    J Cell Biochem; 1989 Feb 06; 39(2):129-37. PubMed ID: 2469691
    [Abstract] [Full Text] [Related]

  • 20. Potent 2'-aminoanilide inhibitors of cFMS as potential anti-inflammatory agents.
    Patch RJ, Brandt BM, Asgari D, Baindur N, Chadha NK, Georgiadis T, Cheung WS, Petrounia IP, Donatelli RR, Chaikin MA, Player MR.
    Bioorg Med Chem Lett; 2007 Nov 15; 17(22):6070-4. PubMed ID: 17904845
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.